Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CBMG Announces Plans to Build US R&D Facility for Immunotherapies

publication date: Oct 8, 2019

Cellular Biomedicine, a US-China biopharma, signed a lease to build a R&D facility in Maryland that will support early US trials of its CAR-T immunotherapy candidates. CBMG has already started China Phase I trials of its CAR-T treatment that was developed in its Shanghai and Beijing R&D facilities. The company focuses on immunotherapies for oncology indications and stem cell treatments for degenerative conditions. It said the US site will facilitate partnerships and innovation along with US development of its products. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.